Key result
CTNNA2 single-nucleotide polymorphisms were associated with psychiatric and cardiovascular phenotypes, with rumination totally mediating the association of rs17019243 with psychiatric symptom scores.
Why the study?
CTNNA2 has been implicated in intrauterine brain development, psychiatric disorders, and cardiovascular diseases, but its gene-wide associations with risk factors and the potential mediating role of rumination remained to be evaluated.
Observational (n=795)
CTNNA2 genetics may serve as biomarkers for psychiatric disorders with perseverative negative thinking, though rumination does not mediate its association with cardiovascular risk scores.
Supports CTNNA2 as potential biomarker for psychiatric-CV comorbidity; leaves open causal inference and practice implications.
AlphaN-catenin gene CTNNA2 has been implicated in intrauterine brain development, as well as in several psychiatric disorders and cardiovascular diseases. Our present aim was to investigate CTNNA2 gene-wide associations of single-nucleotide polymorphisms (SNPs) with psychiatric and cardiovascular risk factors to test the potential mediating role of rumination, a perseverative negative thinking phenotype in these associations. Linear mixed regression models were run by FaST-LMM within a sample of 795 individuals from the Budakalasz Health Examination Survey. The psychiatric outcome variables were rumination and its subtypes, and ten Brief Symptom Inventory (BSI) scores including, e.g., obsessive-compulsive, depression, anxiety, hostility, phobic anxiety, and paranoid ideation. Cardiovascular outcome variables were BMI and the Framingham risk scores for cardiovascular disease, coronary heart disease, myocardial infarction, and stroke. We found nominally significant CTNNA2 associations for every phenotype. Rumination totally mediated the associations of CTNNA2 rs17019243 with eight out of ten BSI scores, but none with Framingham scores or BMI. Our results suggest that CTNNA2 genetics may serve as biomarkers, and increasing the expression or function of CTNNA2 protein may be a potential new therapeutic approach in psychiatric disorders with perseverative negative thinking including, e.g., depression. Generally, an antiruminative agent could be a transdiagnostic and preventive psychopharmacon.
No takes yet. Share an insight, caveat, or question.
Eszlári et al. (2021) conducted an observational in Psychiatric disorders and cardiovascular risk factors (n=795). CTNNA2 single-nucleotide polymorphisms was evaluated on Psychiatric (rumination, BSI scores) and cardiovascular (BMI, Framingham risk scores) outcomes. CTNNA2 single-nucleotide polymorphisms were associated with psychiatric and cardiovascular phenotypes, with rumination totally mediating the association of rs17019243 with psychiatric symptom scores.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: